कंपनी का अवलोकन
Phaos Technology Holdings (Cayman) Limited, operating through its subsidiary Phaos Technology Pte. Ltd., is principally engaged in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products within Singapore. This entity functions within the Healthcare sector, specifically the Medical Devices industry, which implies a focus on specialized equipment and innovations critical for medical diagnostics and research applications. The company maintains a market capitalization of $21.93M and reports an annual revenue (TTM) of $167,707, supported by an employee base of 25 individuals. These financial figures indicate that the company operates at a micro-cap scale, suggesting it is likely in an early-stage development or commercialization phase where revenue generation is limited relative to its valuation metrics.
वित्तीय स्वास्थ्य
The company reports a trailing twelve-month revenue of $167,707 against a net income of $-5,137,064, revealing a severe structural inefficiency where operating costs and expenses vastly exceed total revenue generation. EBITDA stands at $-3,869,313, further highlighting the significant burn rate inherent in the company's current operational model. Free cash flow is negative at $-1,657,362, indicating that the company is consuming cash reserves to fund operations and growth initiatives rather than generating liquidity from its core business activities. Gross margin stands at 22.1%, suggesting that the company retains a modest portion of revenue after direct costs, while the operating margin of -1897.8% and profit margin of 0.0% illustrate extreme operational losses relative to sales volume. The company holds $177,660 in cash against $3.26M in debt, resulting in a debt-to-equity ratio that is technically N/A due to negative equity, which points to a highly leveraged and distressed balance sheet. With a current ratio of 0.40, the company's current assets are insufficient to cover its current liabilities, signaling potential short-term liquidity challenges. Return on Equity is -1073.1% and Return on Assets is -71.2%, metrics that reveal management is currently destroying shareholder and asset value rather than generating returns.
मूल्यांकन आकलन
Trailing P/E and forward P/E ratios are both listed as N/A, reflecting the absence of positive earnings required to calculate these traditional valuation multiples. The price-to-book ratio is -27.23, a negative figure that indicates the market is pricing the company below its book value, often seen in distressed assets or entities with significant accumulated losses. Price-to-sales ratio is 130.77, while EV/EBITDA is -11.44; these alternative metrics suggest the market is valuing the company based on revenue multiples despite its lack of profitability, which is common for high-risk micro-cap biotech or device firms. The stock's 52-week high was $7.39 and the low was $0.53, providing a range of $6.86 within which the security trades. Without a specific current price provided in the source data, the valuation relative to this range cannot be precisely calculated, but the negative P/B and high P/S suggest significant investor skepticism regarding the company's ability to monetize its assets. Beta is listed as N/A, meaning there is no historical data available to quantify the stock's volatility relative to the broader market index.
Growth & Income
Revenue growth year-over-year is -93.1%, while earnings growth is N/A due to negative earnings, indicating that the company is contracting significantly in terms of sales volume. The inability to calculate earnings growth versus revenue growth further underscores the financial distress, as the company is not only shrinking in revenue but also failing to generate any profit. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute any income to shareholders and instead retains earnings, albeit negative ones, to attempt to sustain operations. The overall growth and income profile is characterized by substantial revenue contraction, negative returns across all capital metrics, and an absence of shareholder distributions, painting a picture of a struggling entity with limited financial stability.